THE Therapeutic Goods Administration (TGA) has approved the marketing of GSK's Menveo (meningococcal ACWY oligosaccharide conjugate vaccine) for use in babies from two months old.
This vaccine provides protection against strains A, C, W and Y.
The B, W and Y strains cause most meningococcal cases in Australia.
In 2017, the B strain remains the most prevalent in babies, however an emergence of the W strain has created an increased need for a vaccine to help protect infants against this strain.
The above article was sent to subscribers in Pharmacy Daily's issue from 13 Sep 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Sep 17